AO-10T
Rev. 03/2023

FINANCIAL DISCLOSURE
PERIODIC TRANSACTION REPORT

Report Required by the Ethics in Government Act of 1978 (5 U.S.C. §§ 13101-13111)

*1. First Name	*2. Middle Initial	*3. Last Name	4. Suffix
David	J.	Barron	
*5. Title	*6. District/Court/Unit		*7. Circuit
Chief Judge	Not Applicable		01
8. Report Type	9. Calendar Year	*10. Date Filed	11. Check box if amending prior report and enter date of prior submission.
Periodic Transaction Report	2024	06/24/2024	
*12. Date of First Transaction on this Report		*13. Date of Last Transaction on this Report	
05/30/2024		05/30/2024	

TRANSACTIONS

Any purchase, sale, or exchange that exceeds $1,000 in stocks, bonds, commodities futures, and other securities (Includes those of spouse and dependent children)

A. Description of Assets	B. Transaction Type	C. Date of Transaction	D. Date Notified of Transaction	E. Amount of Transaction
1. Inhibrx Inc. (INBX)	Sold	05/30/2024	05/30/2024	$1,000,001 - $5,000,000
2. New Inhibrx Inc. (INBX)	Exchange	05/30/2024	05/30/2024	$500,001 - $1,000,000
3.				
4.				
5.				
6.				
7.				
8.				
9.				
10.				
11.				
12.				
13.				
14.				
15.				

TRANSACTIONS *Any purchase, sale, or exchange that exceeds $1,000 in stocks, bonds, commodities futures, and other securities (Includes those of spouse and dependent children)*

First Name	Middle Initial	Last Name	Suffix
David	J.	Barron	

	A. Description of Assets	B. Transaction Type	C. Date of Transaction	D. Date Notified of Transaction	E. Amount of Transaction
16.					
17.					
18.					
19.					
20.					
21.					
22.					
23.					
24.					
25.					
26.					
27.					
28.					
29.					
30.					
31.					
32.					
33.					
34.					
35.					
36.					
37.					
38.					
39.					
40.					

TRANSACTIONS *Any purchase, sale, or exchange that exceeds $1,000 in stocks, bonds, commodities futures, and other securities (Includes those of spouse and dependent children).*

First Name David	Middle Initial J.	Last Name Barron	Suffix

	A. Description of Assets	B. Transaction Type	C. Date of Transaction	D. Date Notified of Transaction	E. Amount of Transaction
41.					
42.					
43.					
44.					
45.					
46.					
47.					
48.					
49.					
50.					
51.					
52.					
53.					
54.					
55.					
56.					
57.					
58.					
59.					
60.					
61.					
62.					
63.					
64.					
65.					

TRANSACTIONS *Any purchase, sale, or exchange that exceeds $1,000 in stocks, bonds, commodities futures, and other securities (Includes those of spouse and dependent children).*

First Name David	Middle Initial J.	Last Name Barron	Suffix

	A. Description of Assets	B. Transaction Type	C. Date of Transaction	D. Date Notified of Transaction	E. Amount of Transaction
66.					
67.					
68.					
69.					
70.					
71.					
72.					
73.					
74.					
75.					
76.					
77					
78.					
79.					
80.					
81.					
82.					
83.					
84.					
85.					
86.					
87.					
88.					
89.					
90.					

First Name David	Middle Initial J.	Last name Barron	Suffix

ADDITIONAL INFORMATION OR EXPLANATIONS

- This transaction is a result of a corporate acquisition of Inhibrx by Sanofi. Line 1 lists the sale of Inhibrx shares for cash. Line 2 lists the exchange of old Inhibrx (INBX) shares for new Inhibrx (INBX) shares.
- Contingent value rights (CVRs) were also issued to shareholders as a result of the transaction. They are not reportable at this time as they are tied to future milestones / payment triggers.

CERTIFICATION.
I certify that all information given above (including information pertaining to my spouse and minor or dependent children, if any) is accurate, true, and complete to the best of my knowledge and belief, and that any information not reported was withheld because it met applicable statutory provisions permitting non-disclosure.

NOTE: ANY INDIVIDUAL WHO KNOWINGLY AND WILLFULLY FALSIFIES OR FAILS TO FILE THIS REPORT MAY BE SUBJECT TO CIVIL AND CRIMINAL SANCTIONS (5 U.S.C. § 13106)

**SIGNATURE:*

s/ David J. Barron

Committee on Financial Disclosure
Administrative Office of the United States Courts
Suite G-330
One Columbus Circle, N.E.
Washington, D.C. 20544